Sadao Jinno, MD
Rheumatology · Honolulu, HINPI 1215139571
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,618 of the $6,351 with a category attached, or 88.5%. Sobi, Inc accounts for 91.0% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $5,798, more than ten times the $465 reported in 2023.
Across 28 payments — averaging $226.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$6K
- Amgen$163
- AbbVie$134
- Lilly USA, LLC$111
- AstraZeneca$64
- UCB, Inc.$40
- plus $59 from 3 others
What the payments were for
- Consulting fees$5,61888%
- Food & beverage$73312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 7 | $5,781 |
| Amgen | 3 | $163 |
| AbbVie | 6 | $134 |
| Lilly USA, LLC | 4 | $111 |
| AstraZeneca(2 entities) | 3 | $64 |
| UCB, Inc. | 2 | $40 |
| Abbott | 1 | $21 |
| Mannkind Corporation | 1 | $19 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMJEVITA$117
How this compares
$6,351 in reported general payments places this provider in the 70th percentile of 21 rheumatology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 22 | $161,564 |
| Celecoxib | 92 | $2,651 |
| MethotrexateMethotrexate Sodium | 105 | $2,505 |
| Colchicine | 29 | $2,284 |
| Hydroxychloroquine Sulfate | 24 | $1,572 |
| Prednisone | 171 | $1,403 |
| Allopurinol | 44 | $709 |
| Sulfasalazine | 32 | $473 |
| Methylprednisolone | 14 | $215 |
| Tramadol Hcl | 22 | $163 |
| Leflunomide | 12 | $145 |
| Meloxicam | 13 | $81 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Honolulu
- Scott KawamotoHonolulu$58K
- Daniel BrandtHonolulu$29K
- Kristine UramotoHonolulu$26K
- Deryll AmbrocioHonolulu$21K
- Mari ShiraishiHonolulu$9K
- Devy SetyonoHonolulu$9K
- Heejae JungHonolulu$4K
- Denny NakayamaHonolulu$3K
- Ken ArakawaHonolulu$3K
- Alberto Santos-OcampoHonolulu$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.